Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the real-world effectiveness, safety, and patient compliance of ribociclib combined with an aromatase inhibitor for adjuvant treatment in patients with hormone receptor-positive, HER2-negative early breast cancer at high risk of recurrence. This observational study also compares ribociclib treatment with abemaciclib plus endocrine therapy and endocrine therapy alone, aiming to better understand treatment decisions and clinical adoption in routine practice. The study is conducted across breast centers and gynecological practices to represent typical healthcare settings. Participants receive treatment based on their physicians clinical judgment without randomization or intervention assignment. The study collects data from patients treated with ribociclib plus aromatase inhibitor with or without luteinizing hormone-releasing hormone LHRH, abemaciclib plus endocrine therapy with or without LHRH, or endocrine therapy alone with or without LHRH. Baseline data and follow-up information on adverse events, quality of life, treatment adherence, and socio-economic factors are gathered over time. During the study, participants undergo assessments including evaluation of invasive disease-free survival up to 36 months, quality of life questionnaires, medication adherence reports, and monitoring of adverse events and treatment changes. Data on reasons for treatment decisions, patient perceptions, and healthcare provider involvement are also collected. The study duration extends up to 39 months to provide a comprehensive overview of treatment impact and patient experience in real-world clinical settings.
Actively Recruiting
Researchers are evaluating the performance and safety of Artelac Complete MDO eye drops compared to VISMED MULTI eye drops in managing moderate to severe dry eye disease. This study is a double-masked, randomized, parallel group trial aiming to assess whether Artelac is not inferior to VISMED MULTI in treating this condition, focusing on patients with dry eye secondary to specific disorders. Participants self-administer either Artelac Complete MDO or VISMED MULTI eye drops. Prior to randomization, they will use a preservative-free tear substitute for at least 10 days. The study includes a screening period followed by treatment and assessments over approximately 90 days. The primary outcome measure is the change in total OSDI score from baseline to Day 90. Participants will undergo screening to confirm eligibility, including history review and clinical assessments of dry eye severity. During the study, they will be monitored for symptoms and signs of dry eye, with visits at baseline and Day 90 to measure treatment effects. Safety and adherence are tracked throughout, with the total study duration lasting about three months.